Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05630846 · ClinicalTrials.gov registry record · Phase 2
A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 801
- Enrollment target
NCT05630846 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 801 participants.
The verdict
NCT05630846, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 801 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess immune response and safety of various potencies of a measles, mumps, rubella, and varicella (MMRVNS) vaccines given to healthy children of 4 to 6 years of age.
Interventions
- BIOLOGICAL Investigational MMRV(H)NS vaccine
- BIOLOGICAL Investigational MM(H)RVNS vaccine
- BIOLOGICAL Investigational M(L)M(L)R(L)V(L)NS vaccine
- BIOLOGICAL Marketed MMRV_Lot 1 and Lot 2 vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 801 participants |
| Start Date | 2022-12-14 |
| Est. Completion | 2024-10-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05630846
The ClinicalTrials.gov registry entry for NCT05630846 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 801 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Investigational MMRV(H)NS vaccine is the first listed.
NCT05630846 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05630846 about?
NCT05630846 is a clinical study titled "A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age". The main purpose of this study is to assess immune response and safety of various potencies of a measles, mumps, rubella, and varicella (MMRVNS) vaccines given to healthy children of 4 to 6 years of age.
What is the current status of trial NCT05630846?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 801 participants. The study started on 2022-12-14. Estimated completion is 2024-10-14.
What interventions are being tested in trial NCT05630846?
The interventions under investigation include: Investigational MMRV(H)NS vaccine (BIOLOGICAL), Investigational MM(H)RVNS vaccine (BIOLOGICAL), Investigational M(L)M(L)R(L)V(L)NS vaccine (BIOLOGICAL), Marketed MMRV_Lot 1 and Lot 2 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05630846?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.